Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2025-12-25 @ 10:16 PM
NCT ID:
NCT01181258
Group ID:
EG000
Title:
Patients Receiving NK Cell Infusion
Description:
Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
Rituximab: 375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
Interleukin-2: subcutaneously administered 9 million international units (IU) every other day \* 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight \< 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
Natural killer cells: administered intravenously 1.5 to 8 \* 10\^7 cells/kg on Day 0 (day of NK cell infusion)
Cyclophosphamide: 60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine
Methylprednisolone: 1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion
Fludarabine: 25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
6
Serious Number At Risk:
15
Other Number Affected:
15
Other Number At Risk:
15
Study:
NCT01181258
Results Section:
NCT01181258
Adverse Events Module:
NCT01181258